Advanced search
Publication Cover
Cancer Management and Research Volume 11, 2019 - Issue
Submit an article Journal homepage
83
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method

Yizhao Xie1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
,
Bingxin Gu2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;4 Center for Biomedical Imaging, Fudan University, Shanghai, People’s Republic of China;5 Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, People’s Republic of China
,
Xichun Hu1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
,
Yingjian Zhang2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;4 Center for Biomedical Imaging, Fudan University, Shanghai, People’s Republic of China;5 Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, People’s Republic of China
,
Jian Zhang1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
,
Zhonghua Wang1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
,
Yannan Zhao1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
,
Chengcheng Gong1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
,
Yi Li1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
,
Zhongyi Yang2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;4 Center for Biomedical Imaging, Fudan University, Shanghai, People’s Republic of China;5 Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
&
Biyun Wang1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 6019-6027 | Published online: 02 Jul 2019

References

  • Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(January 2014):505–527. doi:10.1001/jamaoncol.2015.073526181261
  • Chen W, Zheng R, Baade PD, et al. Cancer statistics in China. CA Cancer J Clin. 2016;66(April):115–132. doi:10.3322/caac.2133826808342
  • Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–1948. doi:10.1056/NEJMra100138921067385
  • Li X, Yang J, Peng L, Sahin AA, Huo L. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2016;161(2):279–28727888421
  • Zhang J, Lin Y, Sun XJ, et al. Biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Ann Oncol. 2018;29(8):1741–1747. doi:10.1093/annonc/mdy20929905759
  • Hu X-C, Zhang J, Xu B-H, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015;16(4):436–446. doi:10.1016/S1470-2045(15)70064-125795409
  • Staudacher L, Cottu PH, Diéras V, et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol. 2011;22(4):848–856. doi:10.1093/annonc/mdq46120924076
  • Stover DG, Coloff JL, Barry WT, Brugge JS, Winer EP, Selfors LM. The role of proliferation in determining response to neoadjuvant chemotherapy in breast cancer: a gene expression-based meta-analysis. Clin Cancer Res. 2016;22(24):6039–6050. doi:10.1158/1078-0432.CCR-16-047127330058
  • Tixier F, Le Rest CC, Hatt M, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52(3):369–378. doi:10.2967/jnumed.110.08240421321270
  • Kang SR, Song HC, Byun BH, et al. Intratumoral metabolic heterogeneity for prediction of disease progression after concurrent chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer. Nucl Med Mol Imaging (2010). 2014;48(1):16–25. doi:10.1007/s13139-013-0231-7
  • Zhao Y, Liu C, Zhang Y, et al. Prognostic value of tumor heterogeneity on 18F-FDG PET/CT in HR+HER2− metastatic breast cancer patients receiving 500 mg fulvestrant: a retrospective study. Sci Rep. 2018;8(1):4–10. doi:10.1038/s41598-017-18445-029311719
  • Gong C, Ma G, Hu X, et al. Pretreatment 18 F‐FDG uptake heterogeneity predicts treatment outcome of first‐line chemotherapy in patients with metastatic triple‐negative breast cancer. Oncologist. 2018;23(10):1144–1152. doi:10.1634/theoncologist.2018-000130082489
  • Marinelli B, Espinet-Col C, Ulaner GA, et al. Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. Am J Nucl Med Mol Imaging. 2016;6(2):120–127.27186439
  • Cook GJR, Yip C, Siddique M, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med. 2013;54(1):19–26. doi:10.2967/jnumed.112.10737523204495
  • Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P. A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and 2 pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT trial. Nat Med. 2018;24(5):628–637. doi:10.1038/s41591-018-0009-729713086
  • Son SH, Kim DH, Hong CM, et al. Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast. BMC Cancer. 2014;14(1):585. doi:10.1186/1471-2407-14-58525112709
  • McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–628. doi:10.1016/j.cell.2017.01.01828187284
  • Ellsworth RE, Blackburn HL, Shriver CD, Soon-Shiong P, Ellsworth DL. Molecular heterogeneity in breast cancer: state of the science and implications for patient care. Semin Cell Dev Biol. 2017;64:65–72. doi:10.1016/j.semcdb.2016.08.02527569190
  • Ramos P, Bentires-Alj M. Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene. 2015;34(28):3617–3626. doi:10.1038/onc.2014.31425263438

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.